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Simple ammonium salts acting on 
sigma-1 receptors yield potential 
treatments for cancer and 
depression
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Sigma-1 and sigma-2 receptors are emerging therapeutic targets. We have identified that simple 
ammonium salts bind to these receptors and are effective in vivo. Radioligand binding assays were 
used to obtain structure-activity relationships of these salts. MTS assays were performed to determine 
their effect on growth in MCF7 and MDA-MB-486 cells. Anticancer properties were tested in NMRI 
mice transplanted with a fragment of mouse adenocarcinoma (MAC13). Antidepressant activity 
was tested using the forced-swim test and tail suspension tests. Dipentylammonium (Ki 43 nM), 
tripentylammonium (Ki 15 nM) and trihexylammonium (Ki 9 nM) showed high affinity for the sigma-1 
receptor. Dioctanoylammonium had the highest affinity (K50 0.05 nM); this also showed the highest 
affinity for sigma-2 receptors (Ki 13 nM). Dipentylammonium was found to have antidepressant 
activity in vivo. Branched-chain ammonium salts showed lower affinity. Bis(2-ethylhexyl)ammonium 
(K50 29 µM), triisopentylammonium (K50 196 µM) and dioctanoylammonium showed a low Hill slope, 
and fitted a 2-site binding model for the sigma-1 receptor. We propose this two-site binding can 
be used to biochemically define a sigma-1 receptor antagonist. Bis(2-ethylhexyl)ammonium and 
triisopentylammonium were able to inhibit the growth of tumours in vivo. Cheap, simple ammonium 
salts act as sigma-1 receptor agonists and antagonists in vivo and require further investigation.
The sigma opioid receptor was proposed as a novel fourth opioid receptor in 1976 to account for the behavioural 
effects of N-allylnormetazocine (SKF-10,047) which could not be accounted for by the μ (morphine) receptor or 
κ (ketocyclazocine) receptor1. Rather than causing analgesia, as with morphine, benzomorphans such as SKF-
10,047 and pentazocine cause psychotomimesis. Martin proposed that SKF-10,047 was acting as a sigma opioid 
receptor agonist, in order to cause the psychological and behavioural effects which were observed1. It is now 
recognized that there are two sigma receptors: The sigma-1 receptor consists of a 223 amino acid long protein, 
which shares no homology with any other known mammalian protein2. X-ray crystallography analysis of the 
sigma-1 receptor has revealed a trimeric structure, with each receptor in the trimer having a single transmem-
brane domain anchoring it to the cytosolic side of the endoplasmic reticulum3. N,N-dimethyltryptamine may be 
the endogenous sigma-1 receptor ligand despite having low affinity for the sigma-1 receptor4. TMEM97 has now 
been proposed to be the unrelated “sigma-2 binding site”5.
The sigma-1 receptor has been linked with many diverse disease states and conditions. Sigma-1 receptor 
agonists appear to remedy symptoms of many mental conditions including depression, Alzheimer’s and drug 
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addiction. Conversely, antagonists at the sigma-1 receptor can be used in the diagnosis and treatment of many 
cancers; in addition they also have analgesic properties6.
The efficacy of sigma-1 agonists in the treatment of depression has been recognized retrospectively, as many 
widely used antidepressants have now been shown to also act at the sigma-1 receptor7. Fluoxetine has been found 
to bind the sigma-1 receptor with reasonable affinity (214 nM)8, although affinity for the 5-HT reuptake trans-
porter was much higher (0.81 nM)8.
Whilst the sigma-1 receptor has been mostly studied for its functions within the nervous system, it is also 
found to be very highly expressed in a wide range of human tumours that originate from both neuronal and 
non-neuronal tissues9. This has facilitated the clinical study of cancer through the application of sigma ligands in 
tumour imaging10, and the identification that sigma-1 receptor antagonists are able to prevent tumour growth, 
through calcium signalling, phospholipase C (PLC) activation, ER stress, and caspase activation11,12.
Development of new agents is costly and time-consuming. Leading chemists claim that each new chemical 
entity in drug discovery requires multiple synthetic steps (seven or more) for their production13. There have been 
a number of previous studies looking for a structural relationship between sigma-1 receptor ligands and their 
affinity for the sigma-1 receptor14,15. The importance of the nitrogen atom has been shown for the phenylalkylpip-
eridines and phenylalkylpiperazines14,16. However, evidence exists that more simple molecules can show high 
affinity for the sigma-1 receptor17,18.
We now determine that simple ammonium salts show clear structure-activity relationships for the sigma-1 
receptor. Our simple ammonium salts differ from commonly used sigma-1 receptor ligands, which often contain 
more than one nitrogen and have complex aromatic ring structures; the simple ammonium salts contain only one 
nitrogen, and have simple carbon chains. These compounds were found to have high affinity for the unrelated 
sigma-2 receptor, TMEM975. All but one of the straight-chained ammonium salts described show agonist-like 
profiles during in vitro studies. One of these, dipentylammonium, is shown to have antidepressant activity in vivo 
despite showing little activity towards transporters of 5-hydroxytryptamine (serotonin), dopamine or noradrena-
line. Furthermore, the branched-chain ammonium salts showed antagonist-like properties during in vitro studies 
and the two tested were able to prevent tumour growth in vivo.
Results
Binding to the sigma-1 and sigma-2 receptors. Previous data have shown that MDA-MB-468 cells 
contain high concentrations of sigma-1 receptors (pKd ± SEM of [3H] (+) pentazocine 7.8 ± 0.6, Kd 17 nM, Bmax 
2300 ± 200 fmol.mg−1)19. In contrast, no [3H] (+) pentazocine binding was observed in MCF7 cells, identifying 
these cells to be a good model to study sigma-2 receptor binding. This is in agreement with previous studies9. The 
binding of [3H] DTG to MCF7 cells showed a pKd ± SEM of [3H] DTG 7.92 ± 0.04, Kd = 12 nM, Bmax 1700 ± 400 
fmol.mg−1. We have recently shown that [3H] DTG binding is reduced by (+) pentazocine with low affinity, fur-
ther confirming the absence of sigma-1 receptors from MCF7 cells20.
This systematic study compared affinities of 34 ammonium salts for the sigma-1 and sigma-2 receptors. Those 
of interest were further assessed for cross-reactivity with other systems and in vivo biological activity.
Primary ammonium salts showed increasing affinity associated with increasing molecular weight. The highest 
affinity primary ammonium salt we tested was decylammonium with a Ki of 310 nM (Table 1, Supplementary 
Table ST1, Supplementary Fig. SF1). Affinity for the sigma-2 receptor showed a similar graded but less dramatic 
Ammonium salt
σ-1 R affinity
pKi ± SEM (n)
σ-1 R affinity
(µM)
σ-2 R affinity
pKi ± SEM (n)
σ-2 R 
affinity
(µM)
σ-1 R 
Ki/σ-2 
R Ki
Octyl 6.1 ± 0.3 (4) 0.80 5.2 ± 0.2 (3) 6.2 0.13
Decyl 6.5 ± 0.4 (4) 0.32 5.41 ± 0.07 (3) 3.9 0.081
Dipropyl 5.6 ± 0.2 (6) 2.6 4.10 ± 0.07 (3) 79 32
Dibutyl 6.9 ± 0.4 (6) 0.14 5.64 ± 0.07 (3) 2.3 18
Dipentyl17 7.4 ± 0.5 (6) 0.043 6.9 ± 0.2* (3) 0.12 3.2
Dihexyl 6.8 ± 0.6 (6) 0.14 7.58 ± 0.06* (3) 0.026 0.17
Dioctyl 10.3 ± 0.2 (6) 0.000050 7.9 ± 0.5 (3) 0.014 0.0040
Tributyl 6.9 ± 0.1 (6) 0.13 5.5 ± 0.2* (3) 3.0 0.040
Tripentyl 7.8 ± 0.2 (6) 0.015 6.1 ± 0.1 (3) 0.78 0.020
Trihexyl 8.1 ± 0.4 (6) 0.009 6.63 ± 0.03 (3) 0.23 0.034
Bis(2-ethylhexyl) 4.5 ± 0.3* (5) 29 4.0 ± 0.2* (3) 91 0.29
Triisobutyl 5.1 ± 0.6 (6) 7.9 5.46 ± 0.06 (3) 3.5 2.3
Triisopentyl 4.1 ± 0.4* (6) 79 6.40 ± 0.09* (3) 0.40 200
Tetrapropyl 2.5 ± 0.1 (3) 3,200 3.5 ± 0.2* (3) 310 10
Tetrabutyl 2.8 ± 0.1 (3) 1,600 4.22 ± 0.08* (3) 60 25
Table 1. Affinities of key ammonium salts tested. Affinities for the sigma-1 and sigma-2 receptors (σ-1 R and 
σ-2 R, respectively) are shown as pKi and Ki (µM) values from competition binding assays. Hill slopes were 
determined as unity for all salts tested, except those labelled *. σ-1 R Ki/σ-2 R Ki shows the ratio between Ki 
values. Sigma-1 receptor affinity has been previously published17. These data are reproduced from the PhD 
theses by J.M. Brimson44 and H. Abbas45.
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improvement. Decylammonium was found to have the highest affinity with a Ki of 3.9 µM (Table 1, Supplementary 
Table ST1, Supplementary Fig. SF1).
Secondary ammonium salts bound with much higher affinity to the sigma-1 receptor. Affinity for the sigma 
receptors increased with chain length, with dioctylammonium showing the highest affinity (K50 0.05 nM and 
13 nM, for sigma-1 and sigma-2 receptors respectively) (Table 1, Supplementary Table ST1, Supplementary 
Fig. SF2). Of the compounds tested, dioctylammonium showed the greatest selectivity (245-fold) towards the 
sigma-1 receptor over the sigma-2 receptor. The binding of dioctylammonium to sigma-1 receptors showed 
a particularly low Hill slope (0.43 ± 0.02, mean ± SEM, n = 4). A two-site binding model fits the data better 
(Supplementary Fig. SF3), giving pKi high 11.9 ± 0.3 (50 ± 7% of total binding) and pKi low 9.4 ± 0.2.
Tertiary ammonium salts also showed a graded increase in affinity. Tripentylammonium and trihexylammo-
nium were found to have the highest affinity with Ki values for the sigma-1 receptor of 15 nM and 9 nM, respec-
tively. The affinity for sigma-2 receptors showed a very similar pattern; trihexylammonium was found to have 
highest affinity with Ki of 230 nM. Increasing the chain length above six carbons was detrimental to binding to 
both sigma-1 and sigma-2 receptors (Table 1, Supplementary Table ST1, Supplementary Fig. SF4).
All quaternary ammonium salts tested had low affinity for the sigma-1 receptor. Tetrabutylammonium bound 
with highest affinity with a Ki of 1.6 mM, and there was little increase in affinity as the carbon chain length 
increased, therefore no larger quaternary ammonium salts were tested for sigma-1 receptor affinity. Similarly, 
quaternary ammonium salts showed low affinity for the sigma-2 receptor (Table 1, Supplementary Table ST1, 
Supplementary Fig. SF5).
In addition to these straight-chained ammonium salts, 10 branched-chain salts were tested. These tended to 
have lower affinity for the sigma-1 receptor than comparable straight-chained analogues (Table 1, Supplementary 
Table ST1, Supplementary Fig. SF6). Their affinity for the sigma-2 receptor was not as greatly reduced. 
Triisopentylammonium showed the greatest selectivity towards the sigma-2 receptor, with a 200-fold higher 
affinity for sigma-2 receptors over sigma-1 receptors. The binding of most straight-chained ligands to the sigma-1 
receptors showed a simple displacement with a Hill slope of unity. In contrast, the branched-chain ammonium 
salts appeared to have shallower Hill slopes. A one-sample t test (GraphPad Prism) showed three had a Hill slope 
significantly less than unity at the sigma-1 receptor: bis(2-ethylhexyl)ammonium (0.24 ± 0.14, P = 0.001, n = 5), 
di-sec-butylammonium (0.41 ± 0.12, P = 0.040, n = 3) and triisopentylammonium (0.42 ± 0.12, P = 0.008, n = 6). 
Dicyclohexylammonium showed a low, but not statistically significant Hill slope (0.4 ± 0.2, P = 0.052, n = 5). The 
binding of bis(2-ethylhexyl)ammonium and triisopentylammonium was found to fit a 2-site model in preference 
to a one-site fit. Bis(2-ethylhexyl)ammonium was found to have pKi high 6.4 ± 0.5 (18 ± 6% of total binding) 
and pKi low 4.4 ± 0.3. Similarly, triisopentylammonium was found to have pKi high 5.6 ± 0.4 (70 ± 13% of total 
binding) and pKi low 1.8 ± 0.2. (Supplementary Fig. SF3). Di-sec-butylammonium was found to best fit a one-site 
model.
The Hill slopes of binding to the sigma-2 receptor showed less of a pattern: eleven of the 34 tested showed a 
Hill slope significantly below unity (Supplementary Table ST1). All agents were found to best fit a one-site binding 
model at the sigma-2 receptor. The high affinity of some of these simple ligands led us to further examine their 
profile is a series of tests.
Cellular proliferation. The MTS assay was used to determine whether our sigma receptor ligands affected 
cellular metabolism in MDA-MB-468 cells, which express both sigma-1 and sigma-2 receptors and MCF7 cells, 
which appear to express only sigma-2 receptors. All but one of the straight-chain ammonium salts were unable 
to decrease cell proliferation at concentrations 10 times above the Ki for the relevant receptor (data not shown). 
Due to its high affinity, dioctylammonium was tested at concentrations well above its Ki and it was found able to 
reduce cellular proliferation, albeit with pIC50 value of 5.0 ± 0.2, well above our reported affinity (pKi for the low 
affinity state 9.4).
The branched-chain ammonium salts, bis(2-ethylhexyl)ammonium (pIC50 3.3 ± 0.1), dicyclohexylammo-
nium (pIC50 3.9 ± 0.1) and triisopentylammonium (pIC50 2.96 ± 0.06) caused a dose-dependent reduction in 
cell metabolism in sigma-1 receptor-expressing MDA-MB-468 cells (Fig. 1). They were without effect on MCF7 
Figure 1. Certain ammonium salt sigma-1 receptor ligands reduce cellular metabolism in MDA-MB-468 
cells. Dioctylammonium (n = 4, filled circles), dicyclohexylammonium (n = 4, open circles), bis(2-ethylhexyl)
ammonium (n = 6, filled squares) and triisopentylammonium (n = 6, open squares) reduced cellular activity in 
a concentration-dependent manner. Error bars show SEM. This figure is modified from the PhD thesis by J.M. 
Brimson44.
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cells. This suggests their effects were mediated through the sigma-1 receptor and not the sigma-2 receptor. 
Furthermore, sigma-1 receptor knock down, using a sigma-1 receptor targetting siRNA, caused a shift in the 
pIC50 values for both bis(2-ethylhexyl)ammonium and triisopentylammonium, from 3.37 ± 0.08 to 2.7 ± 0.2 and 
2.9 ± 0.2 to 2.3 ± 0.2 respectively (Fig. 2). Under these conditions, non-targeting control showed 1750 ± 115 fmol.
mg−1 (mean ± SEM) (+) pentazocine binding; sigma-1 siRNA showed 840 ± 200 fmol.mg−1 ± SEM (+) pen-
tazocine binding. The mean difference in binding from 8 independent experiments was 911 ± 151 fmol.mg−1. 
Unpaired t test analysis gave P < 0.0001 (Fig. 1c and19).
Calcium response. MDA-MB-468 cells were loaded with fluorescent Fura-2 AM (Supplementary Methods). 
The branched-chain ammonium salt, bis(2-ethylhexyl)ammonium, did produce a dose-dependent calcium 
response, with pEC50 = 2.9 ± 0.1 (n = 6) (Supplementary Fig. SF7). Triisopentlyammonium also showed a cal-
cium response at concentrations 1 mM and above (data not shown). No other ammonium salt was able to increase 
cytoplasmic calcium, even at a concentration 100 times the Ki (data not shown). We were unable to assess the 
calcium response to dioctylammonium, as precipitation was observed in the calcium buffer (data not shown).
Ammonium salt specificity for the sigma receptors. Having determined that these simple ammonium 
salts are non-toxic in vitro and some have high affinity for the sigma receptors, we sought to determine whether 
these agents also bound other targets. We chose to study dipentylammonium and tripentylammonium salts from 
the straight-chained ammonium salts and bis(2-ethylhexyl)ammonium and triisopentylammonium from the 
Figure 2. Sigma-1 receptor siRNA hinders the ability of (a) bis(2-ethylhexyl)ammonium and (b) 
triisopentylammonium to reduce cellular metabolism in MDA-MB-468 cells. Levels of binding of 30 nM [³H] 
(+) pentazocine (c) are also shown. SiRNA targeting the sigma-1 receptor caused a shift in the pIC50 for bis(2-
ethylhexyl)ammonium from 3.37 to 2.7 (P = 0.044, unpaired t-test), and for triisopentylammonium from 2.9 
to 2.3 (P = 0.0095, unpaired t-test). Error bars show SEM, n = 3. SiRNA also caused a reduction in the sigma-1 
receptor number, as monitored using a fixed concentration (30 nM) of [³H] (+) pentazocine (P < 0.0001, 
unpaired t-test, n = 8).This figure is reproduced from the PhD thesis by J.M. Brimson44. Panel (c) has been 
previously presented19.
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branched-chain ammonium salts. In terms of “druglikeness”, the free amine dipentylamine fits well into the lim-
itations proposed by Lipinski21, including a partition coefficient (logP) value of 3.82. In contrast, tripentylamine, 
bis(2-ethylhexyl)amine and triisopentylamine, have logP values above 5 (6.44, 6.64 and 5.89, respectively) (ACD 
prediction, (www.chemspider.com)), outside the Lipinski guidelines. The partition coefficients of the ammonium 
salts at pH 7.4 (logD (7.4)) was as follows: dipentylammonium 0.65; tripentylammonium 3.73; bis(2-ethylhexyl)
ammonium 3.38 and; triisopentylammonium 2.68 (ACD prediction, (www.chemspider.com)). According to 
Clark’s 5 “rules of thumb” a logD (7.4) of 1–3 is favoured. In addition, he suggests that a charge of +1 aids access 
to the brain22.
Muscarinic receptors. MDA-MB-468 cells do not express muscarinic receptors. We used rat brain homoge-
nates to assess muscarinic receptor binding. The non-selective muscarinic antagonist, atropine, bound with 
high affinity (pKi 9.4 ± 0.3, n = 4). Dipentylammonium (pKi 3.4 ± 0.2, n = 5) and tripentylammonium (pKi 
4.3 ± 0.4, n = 4) showed low affinity for the muscarinic receptor, similar to rimcazole (pKi 4.5 ± 0.1, n = 7) and 
1-(4-iodophenyl)-3-(2-adamantyl)guanidine (IPAG), a second sigma-1 receptor antagonist (pKi 4.3, n = 1). 
Bis(2-ethylhexyl)ammonium (pKi 3.9 ± 0.2, n = 6) and triisopentylammonium (pKi 3.60 ± 0.11, n = 5) also had 
similar affinities. Of the ammonium salts tested, the straight-chained ammonium salts dipentylammonium and 
tripentylammonium were the most selective for the sigma-1 receptor over the muscarinic acetylcholine recep-
tor. Of the branched-chain ammonium salts, triisopentylammonium was more selective than bis(2-ethylhexyl)
ammonium (Table 2). Dipentylammonium, tripentylammonium and triisopentylammonium were more selective 
for sigma-1 receptors than rimcazole (Table 2).
Straight-chained ammonium salts as sigma-1 receptor agonists and antidepressants. We have 
determined that our simple ammonium salts show moderate to high affinity for the sigma receptors. Based on 
MTS data with MCF7 cells, they appear to show no toxicity. We have, therefore assessed these compounds for 
their behavioural effects using the forced-swim test23 and the tail suspension test24, the most used animal models 
for screening antidepressants.
Five groups of animals (5 animals per group) were submitted to the forced-swim test. Control mice (10 ml.
kg−1 saline) exhibited despair behaviour, remaining still (only making movements to keep their head above the 
water) for 233 ± 10 seconds out of a total of six minutes in the water. The selective serotonin reuptake inhib-
itor, fluoxetine (10 mg.kg−1), significantly reduced the time spent immobile to 153 ± 19 seconds (P = 0.0022). 
Similarly, dipentylammonium (5 mg.kg−1) significantly reduced the time spent immobile to 80 ± 13 seconds 
(P < 0.0001) (Fig. 3). The sigma-1 receptor antagonist N’-[2-(3,4-dichlorophenyl)ethyl]-N,N,N’-trimethylethane- 
1,2-diamine (BD1047) alone at 4 mg.kg−1 had no significant effect, immobility time being 217 ± 17 seconds 
(P > 0.99). However, a 4 mg.kg−1 dose of the sigma-1 receptor antagonist BD1047 prevented a 5 mg.kg−1 dose 
of dipentylammonium from having any effect, immobility time was 185 ± 5 seconds (P = 0.0001, compared to 
dipentylammonium alone), indicating that the effects of dipentylammonium were reversed (Fig. 3). In contrast, 
tripentylammonium did not have any significant effect on the despair like behaviour of the mice (at doses up to 
10 mg.kg−1), as measured by the immobility time in the forced-swim test, and was therefore not tested further.
Dipentylammonium was also tested in the tail suspension test, in which four groups of mice were suspended 
by their tails for a period of six minutes. Despair behaviour is interpreted as time spent completely immobile (not 
struggling to escape). Control mice (10 ml.kg−1 saline, n = 10) exhibited despair behaviour remaining immobile 
for 235 ± 19 seconds (Fig. 4). As with the forced-swim test, treatment with fluoxetine (10 mg.kg−1, n = 10) resulted 
in a significant decrease in time spent immobile (126 ± 22 seconds, P = 0.005). Dipentylammonium (5 mg.kg−1, 
n = 10) also resulted in a significant decrease in time (116 ± 7 seconds, P = 0.0001). Injecting the sigma-1 recep-
tor antagonist BD1047 (4 mg.kg−1) partially reversed the response to dipentylammonium (5 mg.kg−1) (n = 5), 
resulting in an immobility time of 182 ± 30 seconds (P = 0.358, compared to control). Dipentylammonium alone 
(5 mg.kg−1) or in combination with BD1047 (4 mg.kg−1) had no effect on locomotion (control 140 ± 15 events 
in 15 minutes, dipentylammonium 128 ± 19 events in 15 minutes (P = 0.82), dipentylammonium plus BD1047 
114 ± 14 events in 15 minutes (P = 0.43), data not shown).
Compound
σ -1 R affinity
pKi ± SEM (n)
σ -1 R affinity
Ki (µM)
mACh R affinity 
pKi ± SEM (n)
mACh R 
affinity Ki (µM)
mACh R 
Ki/σ-1 R Ki
Atropine 4.5 ± 0.4 (4) 31 9.4 ± 0.3 (4) 0.0004 0.000012
Rimcazole 6.2 ± 0.2 (7) 0.60 4.49 ± 0.10 (7) 32 53
Dipentyl
ammonium 7.4 ± 0.5 (6) 0.043 3.4 ± 0.2 (5) 380 8840
Tripentyl
ammonium 7.8 ± 0.2 (6) 0.015 4.3 ± 0.4 (4) 47 3130
Bis(2-ethylhexyl)
ammonium 4.5 ± 0.3* (5) 29 3.9 ± 0.2 (6) 120 4.1
Triisopentyl
ammonium 4.1 ± 0.4* (6) 79 3.60 ± 0.11 (5) 251 3.4
Table 2. Selectivity of sigma-1 receptor ligands for the sigma-1 receptor (σ-1 R) over the muscarinic 
acetylcholine receptor (mACh R). Affinities for the sigma-1 and muscarinic acetylcholine receptors (σ-1 R and 
mACh R, respectively) are shown as pKi and Ki values from competition binding assays. mACh R Ki/σ-1 R Ki 
shows the ratio between Ki values. These data are reproduced from the PhD thesis by J.M. Brimson44.
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Effects on monoamine transporters. The observation that dipentylammonium was effective in vivo 
led us to determine whether it acts on amine transporters. In contrast to fluoxetine, dipentylammonium was 
found to act very weakly in serotonin reuptake assays. The IC50 for fluoxetine (pIC50 7.1 ± 0.1, n = 6, IC50 83 nM) 
was similar to previously published data (87 nM25), whereas dipentylammonium was some 7,000-fold weaker 
(pIC50 3.0 ± 0.2, n = 4, IC50 1.1 mM) (Fig. 5a). Equally, dipentylammonium was ineffective against the dopamine 
transporter (pIC50 3.2 ± 0.2, n = 5, IC50 0.6 mM), unlike GBR-12935 which inhibited dopamine transport (pIC50 
7.12 ± 0.06, n = 6, IC50 76 nM), in close agreement with previously published results (50 nM26) (Fig. 5b). Finally, 
dipentylammonium was tested against the noradrenaline transporter. In contrast to desipramine, which potently 
inhibited noradrenaline transport (pIC50 8.05 ± 0.14, n = 3, IC50 9 nM), dipentylammonium interacted weakly 
(pIC50 3.6 ± 0.1, n = 3, IC50 0.2 mM) (Fig. 5c). The data for desipramine are in close agreement with previously 
published data (Ki 4.3 nM27).
Effects of branched-chain ammonium salts of tumour growth. MAC13 assay; in vitro assay. We 
have shown above that bis(2-ethylhexyl)ammonium and triisopentylammonium both cause a reduction of met-
abolic activity of MDA-MB-468 cells in the MTS cell survival assay. We subsequently wanted to test their effects 
Figure 3. The effect of dipentylammonium (DPA, 5 mg.kg−1) and sigma-1 receptor antagonist BD1047 (4 mg.
kg−1) on despair behaviour in mice subjected to the forced-swim test. The control consisted of 10 ml.kg−1 
saline; fluoxetine (10 mg.kg−1) was used as a positive control. Five mice were used for each data point. Error 
bars show SEM. ANOVA followed by Bonferroni post hoc multiple comparison gave: *control vs fluoxetine, P 
0.0022; **control vs dipentylammonium, P < 0.0001; control vs BD1047, P = 0.13; ##dipentylammonium vs 
BD1047 + dipentylammonium, P = 0.0001. This figure is reproduced from the PhD thesis by J.M. Brimson44.
Figure 4. The effect of dipentylammonium (DPA, 5 mg.kg−1) and sigma-1 receptor antagonist BD1047 (4 mg.
kg−1) on despair behaviour in mice subjected to the tail suspension test. The control consisted of an injection of 
10 ml.kg−1 saline; fluoxetine (10 mg.kg−1) was used as a positive control. Ten mice were used for each data point, 
except BD1047 + dipentylammonium (n = 5). Error bars represent SEM. ANOVA followed by Bonferroni’s post 
hoc multiple comparison gave: **control vs fluoxetine P = 0.005, **control vs dipentylammonium, P = 0.0001; 
control vs BD1047 + dipentylammonium, P = 0.358; dipentylammonium vs BD1047 + dipentylammonium, 
P = 0.15. This figure is reproduced from the PhD thesis by J.M. Brimson44.
7Scientific RepoRtS |         (2020) 10:9251  | https://doi.org/10.1038/s41598-020-65849-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
on tumours in vivo using MAC13 cell transplant28. Initially MAC13 cells were tested for sigma 1 receptor expres-
sion, using radioligand saturation binding. [3H] (+) pentazocine saturation resulted in mean ± SEM Bmax of 
1310 ± 140 fmol.mg−1, and the mean ± SEM pKd was 7.4 ± 0.1 (n = 3). Both bis(2-ethylhexyl)ammonium and 
triisopentylammonium caused a reduction in MAC13 cell metabolism in vitro (Fig. 6), with mean ± SEM pIC50 
(n = 6) values of 5.3 ± 0.2 and 4.4 ± 0.2 respectively. In this respect, MAC13 cells are more sensitive to our ligands 
than MDA-MB-468 cells (pIC50 3.3 and 2.96, respectively, see above).
Figure 5. The effects of dipentylammonium and triisopentylammonium on serotonin, dopamine and 
norepinepherine reuptake. (a) fluoxetine (open squares) dose-dependently prevents serotonin reuptake (IC50 
83 nM), whereas dipentylammonium (open circles) and triisopentylammonium (closed squares) required 
a far higher concentration to prevent any serotonin uptake (IC50 1.1 mM and IC50 7.8 mM respectively). (b) 
GBR-12935 (open squares) inhibited dopamine transport with IC50 of 76 nM whereas dipentylammonium 
(open circles) and triisopentylammonium (closed squares) required a far higher concentration to prevent 
any dopamine uptake (IC50 0.6 mM and IC50 1.6 mM respectively). (c) Desipramine (open squares), potently 
inhibited norepinepherine (NE) reuptake with IC50 9 nM, whereas dipentylammonium (open circles) and 
triisopentylammonium (closed squares) required a far higher concentration to prevent any norepinepherine 
uptake (IC50 0.2 mM and IC50 7.8 mM respectively).
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MAC13 assay; in vivo assay. MAC13 tumours were established in the mice 12 days before treatment with the 
ammonium salts began. Daily treatment with 10 mg.kg−1 of bis(2-ethylhexyl)ammonium and triisopentylammo-
nium resulted in a statistically significant reduction in tumour growth compared to vehicle control treated ani-
mals (P < 0.001) (Fig. 7), suggesting that the two ammonium salts exhibit anti-tumour properties similar to that 
seen with the sigma-1 receptor antagonists IPAG and rimcazole11,12. In addition, the animals showed no negative 
signs to the use of these drugs: grooming activity was maintained during the study (data not shown).
Discussion
We have performed structure-activity relationship study using 34 simple ammonium salts for sigma-1 and 
sigma-2 receptor affinity. Our molecules are far more simple than the pharmacophore model previously proposed 
for the sigma-1 receptor29. The major findings of this study were that several salts show high affinity for these 
receptors. Selectivity between the ammonium salts ranged from 245-fold preference for the sigma-1 receptor 
(dioctylammonium) to a 200-fold preference for the sigma-2 receptor (triisopentylammonium). We also identi-
fied branched-chained ammonium salts have lower affinities than the straight-chained ammonium salts for the 
sigma-1 receptor. However, branched-chain ammonium salts, along with the outlier dioctylammonium, showed 
a binding profile more in line with what has been previously seen with antagonists such as IPAG and rimcazole19. 
The binding profile of all-but-one (dioctylammonium) of the straight-chained ammonium salts showed a sim-
ple profile with Hill slope of unity, whereas branched-chain ammonium salts bound with a low Hill slope. This 
appears to be a novel means to distinguish antagonists from agonists using in vitro binding assays and identifies 
most straight-chained ammonium salts as agonists and the branched-chain ammonium salts as antagonists at this 
receptor. Further evidence is provided by the observation that, while binding the receptor, the straight-chained 
ammonium salts did not effect calcium influx or reduce metabolic activity (excepting dioctylammonium, which 
reduced metabolic activity; we were unable to obtain calcium data for this compound, as precipitation was 
observed in this assay), whereas some of the branched-chain ammonium salts did, as is the case for antagonists11.
Figure 6. The effects of bis(2-ethylhexyl)ammonium and triisopentylammonium on metabolism of MAC13 
cells in the MTS assay. Bis(2-ethylhexyl)ammonium (open circles) had a mean pIC50 of 5.3 ± 0.2, and 
triisopentylammonium (filled squares) had a mean pIC50 of 4.4 ± 0.2 from 6 independent assays. This figure is 
modified from the PhD thesis by J.M. Brimson44.
Figure 7. The prevention of MAC13 tumour growth in vivo by bis(2-ethylhexyl)ammonium (open circles) 
and triisopentylammonium (filled squares) compared to vehicle treated mice (filled circles). Drug treatment 
commenced 12 days after implantation of the tumour. Error bars represent SEM from 6 mice. *Statistically 
significant tumour growth from day 12, determined using 2-way repeated measures ANOVA with Tukey’s post 
hoc test, P < 0.001. #Statistically significant reduction in tumour growth compared to the equivalent day of in the 
control, P < 0.001. This figure is modified from the PhD thesis by J.M. Brimson44.
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Quaternary ammonium salts showed very low affinity for both sigma receptors. However, tetrapropylammo-
nium and tetrabutylammonium are frequently used at mM concentrations for blocking potassium channels30 and 
NMDA channels31. The effects of these quaternary ammonium salts on sigma receptors could be relevant when 
they are being used to block the channels.
It has been shown previously that sigma-1 receptor ligands such as (+) pentazocine and 1 S,2R-cis-N-[2-
(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)- cyclohexylamine (BD737) are capable of affecting 
muscarine-induced intracellular calcium changes in SH-SY5Y neuroblastoma cells which have been shown to 
express the M1 and M3 subtypes of the muscarinic acetylcholine receptor32. These changes could not be reversed 
by sigma-1 receptor antagonist haloperidol. Therefore, it was deduced that (+) pentazocine (pKi 6.29 ± 0.0632) 
and BD737 were antagonists at the muscarinic receptor. Our binding data suggest that these simple ammonium 
salts have lower affinity for the muscarinic receptor than rimcazole and (+) pentazocine, suggesting they are more 
selective than this widely used ligand. Dipentylammonium has a pKi of 7.4 for the sigma-1 receptor17, which is 
significantly higher than that of rimcazole (pKi 6.5). It also has a significantly lower affinity for the muscarinic 
receptor with a pKi 3.4 compared to rimcazole with a pKi of 4.5. Therefore, dipentylammonium shows greater 
selectivity than (+) pentazocine, haloperidol and rimcazole.
We have previously shown that IPAG regulates intracellular calcium in a manner regulated by cholera toxin19. 
The concentrations required to effect calcium signalling (pEC50 = 3.9, EC50 123 µM) and reduce cellular metabolic 
activity (pEC50 = 4.6, EC50 24 µM) were significantly higher than the equilibrium binding constants (pKi high 
12.8, Ki high 175 fM and pKi low 6.8, Ki low 168 nM)19. We describe similar observations here: Bis(2-ethylhexyl)
ammonium, dioctylammonium and triisopentylammonium all required concentrations higher than their bind-
ing affinities to effect a decrease in cellular metabolism; only dicyclohexylammonium required similar concentra-
tions. This suggests that the equilibrium binding affinities of certain compounds may not represent the binding 
affinity to the active form of a receptor. The induction of a high-affinity state accompanied by desensitisation 
following prolonged incubation with ligands has previously been observed with a limited number of other recep-
tors, including the nicotinic acetylcholine receptor33, µ-opiate receptor34 and GABA receptor35. Whilst outside the 
remit of this publication, we suggest that these observations are further investigated.
There is much evidence to suggest that the sigma-1 receptor is involved in depressive-like behaviours. Sigma-1 
knock-out mice show a depressive-like phenotype36 and previous studies have identified sigma-1 receptor ago-
nists, such as igmesine, SKF-10,047, and dehydroepiandrosterone sulphate, have antidepressant-like properties 
in the forced-swim test assay; furthermore, sigma-1 receptor antagonists such as progesterone or BD1047 reverse 
these effects37. It has previously been shown that dipentylammonium has sigma-1 receptor dependant neuroac-
tive properties17. Our in vivo results suggest that one of these simple ammonium salts, dipentylammonium, is a 
potential antidepressant acting through the sigma-1 receptor, since the antidepressant-like effects were reversed 
by BD1047.
Dipentylammonium required very high doses to have any effects on monoamine transporters, excluding 
them as targets for the effects observed. Neither dipentylammonium per se nor in combination with BD1047 
had an effect on locomotion suggesting that neither have psychostimulant or psychoinhibitory effects, providing 
strong evidence that dipentylammonium causes its antidepressant effects through a sigma-1 receptor-mediated 
mechanism.
Despite having an affinity similar for the sigma-1 receptor to that of dipentylammonium, tripentylammonium 
failed to reduce despair behaviour in mice subjected to the forced-swim test. This can be explained by the phys-
icochemical properties of the two salts: dipentylammonium met the guidelines proposed by Lipinski21, whereas 
tripentylammonium did not.
Our in vitro data for some ligands suggests that they behave as antagonists at the sigma-1 receptor. The bind-
ing profiles of bis(2-ethylhexyl)ammonium and triisopentylammonium mimic other sigma-1 receptor antago-
nists such as IPAG and rimcazole, with shallow Hill slopes and possible multiple binding states19, they are able 
to induce a calcium response, as are other antagonists such as IPAG11. Furthermore, treatment of MDA-MB-468 
cells with these branched-chain ammonium salts resulted in a reduction of cellular metabolism, which could 
be reversed by sigma-1 receptor knock-down using siRNA selective for the sigma-1 receptor. Sigma-1 recep-
tor antagonists IPAG and rimcazole have previously been shown to reduce tumour growth in vivo11. We were 
able to carry out in vivo studies of tumour growth using MAC13 tumours, implanted into NMRI mice. Both 
bis(2-ethylhexyl)ammonium and triisopentylammonium were able to prevent tumour growth in vivo in much 
the same was as with other studies using sigma-1 receptor antagonists.
conclusion
We have identified a non-toxic, high affinity sigma-1 receptor ligand, dipentylammonium, which possesses 
potent antidepressant activity in animals in vivo. Dipentylammonium shows low affinity for classic monoamine 
transporters yet high affinity for the sigma-1 receptor. Further development of this molecule should be carried out 
to determine whether this compound can proceed into clinical trials as an antidepressant. We have also identified 
2 potential anticancer agents, which act as sigma-1 receptor antagonists: bis(2-ethylhexyl)ammonium and triiso-
pentylammonium. These too, should be further investigated as to whether they may have clinical use.
Materials and methods
General materials. Tissue culture media, antibiotics, trypsin and serum were purchased from Invitrogen 
(Paisley, UK). IPAG (1-(4-iodophenyl)-3-(2-adamantyl)guanidine), purchased from Tocris Bioscience, Bristol, 
UK, was dissolved in DMSO. [3H] (+) pentazocine ((1 S,9 S,13 S)-1,13-dimethyl-10-(3-methylbut-2-en-1-yl)-10-
azatricyclotrideca-2,4,6-trien-4-ol) (specific activity 47.6 Ci.mmol-1) and [5-3H(N)]- 1,3-Di-O-tolylguanidine 
(specific activity 32.2 Ci.mmol−1) (DTG) were purchased from Perkin Elmer (Beaconsfield, UK). The simple 
amines were purchased from Sigma-Aldrich (Dorset, UK), Fluka (Sigma-Aldrich, Dorset, UK) or Acros Organics 
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(Fisher Scientific, Loughborourgh, UK) as either hydrochloride salts (HCl•) or as a free base amines. The free 
base amines were made soluble in water by making the HCl salt: 5 ml of free base amine was dissolved in 15 ml of 
ether, and hydrochloric acid was added slowly until the mixture turned acidic, measured using universal indica-
tor paper (Sigma-Aldrich, Dorset, UK). The resulting solid was filtered and any remaining solvent was removed 
under vacuum. If the product was a liquid at room temperature, the solvents were removed under vacuum. Other 
reagents were purchased from Sigma-Aldrich (Poole, UK). Before use, drugs were dissolved in an appropriate 
vehicle and diluted into assay buffer, and the pH of each solution was determined and adjusted to 7.4.
Tissue culture. MDA-MB-468 and 293 cells (ATCC LGC Promotech, UK) and MCF7 cells (a kind gift from 
Professor Weiguang Wang, University of Wolverhampton) were maintained in DMEM, high glucose (41965-062) 
supplemented with 10% foetal calf serum. Cells were cultured at 37 °C in a humidified incubator with 5% CO2. 
The MDA-MB-468 cells were permeabilised (5 pulses at 3.75 KV.cm−1) and washed in Tris(hydroxymethyl)ami-
nomethane (Tris) buffered saline (TBS) (10 mM Tris, 0.9% NaCl, pH 7.4) before use in binding assays to remove 
any endogenous GTP. MCF7 cells were suspended in sigma-2 assay buffer (50 mM Tris-HCl; pH 8.0), sonicated 
(1 minute) and the homogenate was centrifuged (22,000 g, 20 min, 4 °C). The supernatant was discarded, and the 
pellet was suspended in sigma-2 assay buffer.
Saturation binding. Sigma-1 binding. Assays (100 μl) were performed in TBS using 0–300 nM [3H] (+) 
pentazocine at room temperature for two hours as previously described17,19. Non-specific binding was determined 
using 100 μM rimcazole (9-[3-(cis−3, 5-dimethyl-1-piperizinyl)propyl]-9H-carbazole dihydrochloride). Assays 
were terminated by addition of ice-cold TBS and filtration, using a cell harvester, through glass fibre filters (GF/B, 
Sigma-Aldrich, Poole, UK). Tubes and filter discs were washed (2 ×3 ml) with ice-cold TBS, and the filter discs 
dried under vacuum. Scintillation counting was carried out after overnight incubation of the discs with ProSafe 
FC + cocktail (Meridian Biotechnologies Ltd, Tadworth, UK).
Sigma-2 binding. Assays (100 μl) were performed at room temperature for two hours with [3H] DTG in the 
presence of DMSO (10% final concentration). Nonspecific binding was determined using 100 μM reduced halop-
eridol. No sigma-1 receptor “masking agent” (e.g., (+) pentazocine) was used, as this adversely affects the deter-
mination of Kd and Ki values at the sigma-2 receptor20. Assays were terminated by addition of ice-cold sigma-2 
wash buffer (150 mM NaCl, 10 mM Tris-HCl; pH 7.2) and filtration, using a cell harvester, through glass fibre 
filters (GF/C, Sigma-Aldrich, Poole, UK). Tubes and filter discs were washed (2 ×3 ml) with ice-cold wash buffer, 
and the filter discs dried under vacuum. Scintillation counting was carried out after overnight incubation of the 
discs with ProSafe FC + cocktail.
Competition assays. Competition assays (100 μl) were performed using a final assay concentration of 
30 nM [3H] (+) pentazocine or 10–50 nM [3H] DTG. The assay was then allowed to equilibrate at room temper-
ature for four hours. After equilibration, the cells were harvested through GF/B ([3H] (+) pentazocine) or GF/C 
([3H] DTG) glass fibre filters, washing 3 times. Non-specific [3H] (+) pentazocine binding was determined using 
100 μM rimcazole whereas non-specific [3H] DTG binding was determined using 100 μM reduced haloperidol. 
Under these conditions less than 10% of the [3H] (+) pentazocine or [3H] DTG was bound.
Muscarinic receptor binding assays. Rat brain membranes were prepared from freshly killed rats. Rats 
were exposed to an increasing concentration of carbon dioxide until dead in accordance with Schedule 1 of 
Animals (Scientific Procedures) Act 1986 and decapitated. This method was approved by Bath University Ethics 
Committee. The brain was immediately removed and placed on ice with TBS. The brain was homogenised in 
10 ml of ice cold TBS by a Teflon-in-glass homogeniser for two 30 s periods, the homogenates were centrifuged at 
40,000 g for 30 minutes at 4 °C. The resultant supernatant was discarded and the pellets resuspended by homoge-
nisation in fresh TBS. 1.35 nM [3H] L-quinuclidinyl [phenyl-4-3H] benzilate (specific activity 48.0 Ci.mmol−1, GE 
Healthcare, Little Chalfont, UK) (pKd 9.5 ± 0.1, n = 4 data not shown), was incubated with rat brain membranes 
(0.5 mg.ml−1) to which varying concentrations of ammonium salt compounds were added as with the sigma-1 
receptor competition assays. The membranes were incubated and harvested as with the [3H] (+) pentazocine 
binding assays.
MTS cellular metabolic activity assay. Cells (10,000 cells per well, 100 μl) were seeded into 96-well plates 
and allowed to adhere overnight. The following day drugs were added and cells were permitted to proliferate for 
24 hours before the addition of 10 μl CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay reagent 
(Promega, Southampton, UK) as previously described11. Absorbance (490 nm) readings were taken at 0, 1, 2 and 
3 hours to monitor formazan formation and rates of metabolic activity were compared.
Vector constructs. The human dopamine transporter gene, kindly provided by Professor De Felice of 
Virginia Commonwealth University, was released from the pGEX 3Z vector using the KpnI and XbaI restriction 
enzymes in a sequential digestion. The DNA fragment was purified by agarose gel electrophoresis, and inserted 
into the mammalian expression vector, pcDNA3.1, at the KpnI and XbaI sites. Cloning success was checked using 
restriction and sequencing analysis.
The human serotonin “Addgene plasmid 15483” and norepinephrine “Addgene plasmid 15475” transporters 
were obtained in the pcDNA3.1 vector from Addgene38,39.
The sigma-1 siRNA PSilencer plasmid and nontargeting siRNA control were kindly provided by Dr 
Christopher Palmer (London Metropolitan University, UK).
1 1Scientific RepoRtS |         (2020) 10:9251  | https://doi.org/10.1038/s41598-020-65849-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Transporter studies. Individual 293 cell line clones stably expressing the human dopamine trans-
porter, human 5-HT transporter or human noradrenaline transporter were created using Lipofectamine 2000 
(Invitrogen, Gibthai, Bangkok). The 293 cells were plated in 6-well plates at 2.5×105 cells per well, and allowed to 
adhere overnight. The plasmid constructs were then mixed with Lipofectamine as instructed by the manufacturer 
and the 293 cells transfected. The following day the cells were harvested, diluted 10-fold and re-plated in 6-well 
plates before being allowed to adhere overnight. The following day the transfected cells were treated with G418 
(Geneticin) (Invitrogen, Gibthai, Bangkok) to begin selection for positive clones. The cells were incubated for 1 
to 2 weeks, with the G418-containing media being replaced every 2 days. Once colonies of resistant cells began to 
appear, they were isolated using sterile cloning rings and transferred to 96-well plates. Each clone was expanded 
until enough cells were available to verify the expression of the monoamine transporters. The expression was 
assayed using reverse transcriptase PCR and with the monoamine transporter assay (Molecular Devices, Tokyo 
Japan).
Monoamine transporter assay. The 293 cells stably expressing human dopamine, 5-HT or noradrenaline 
transporters respectively were plated in black-walled 96-well plates at approximately 6,000 cells per well. Once 
adhered, the media was removed, cells washed with phosphate buffered saline (PBS) and 50 μl Hank’s buffered 
saline (HBSS) added to each well. Drugs were diluted to 2× concentration in HBSS-0.1% BSA and 50 μl were 
pipetted into each well. Control wells (cells without any drugs) contained 100 μl HBSS-0.05% BSA. The cells 
were incubated with the drugs for 30 minutes before the addition of 100 μl per well of fluorescent monoamine 
analogue dye, which is recognised and transported by all three transporters, and with cell impermeable quencher 
(homogeneous Neurotransmitter Transporter Uptake Assay Kit, #R8174, Molecular Devices, Tokyo, Japan). The 
cells were then incubated for a further 15 minutes at 37 °C in the dark before the fluorescence was measured in a 
microplate reader (excitation: 440 nm, emission: 520 nm). Uptake of the dye was compared to the control wells to 
calculate the % dye uptake for each drug concentration. Each data point was obtained from at least 3 independent 
determinations.
Sigma-1 receptor knock down. Sigma-1 receptor knock down was carried out as previously described19,40. 
Jet-PEI DNA transfection reagent was used to transfect MDA-MB-468 cells, according to the the protocol in 
the Jet-PEI handbook (Autogen Bioclear, Calne, UK). 24–48 h post transfection sigma-1 receptor activity was 
assessed. Sigma-1 receptor expression in permeabilised MDA-MB-468 cells was measured using 30 nM [3H] (+) 
pentazocine.
Test for antidepressant activity. Animals. Males from an inbred strain of albino mice (originating 
from the Laca stock) weighing between 22 and 30 g bred in the Central Animal House (CAH) facility of Panjab 
University, Chandigarh, were used as previously described41. The animals were housed under standard laboratory 
conditions and maintained on natural light and dark cycle, and had free access to food and water. Animals were 
acclimatised to laboratory conditions before the experiment. Each animal was used only once. All the experi-
ments were carried out between 09:00 and 15:00 h. The experimental protocols were approved by the Institutional 
Animal Ethics Committee, Panjab University and conducted according to the Indian National Science Academy 
Guidelines (INSA) for the use and care of experimental animals.
Drugs. All drugs were dissolved in normal saline and different doses were administered intraperitoneally in a 
fixed volume of 1 ml.100 g−1 body weight 30 minutes before the animals were subjected to the test. BD1047 (N’-[2-
(3,4-dichlorophenyl)ethyl]-N,N,N’-trimethylethane-1,2-diamine) was used as a sigma-1 receptor antagonist.
Forced-swim test. Mice were placed inside a rectangular glass jar (25 × 12 × 25 cm) containing water at a depth 
of 15 cm maintained at 24 ± 1 °C for a period of 6 minutes as previously described41. Each mouse was judged to 
be immobile when it ceased struggling and remained floating motionless in water, making only those movements 
necessary to keep its head above water. The total immobility period was recorded and compared to vehicle control 
group.
Tail suspension test. Mice were suspended 58 cm above a table top by using adhesive tape placed approximately 
1 cm from the tip of the tail for a period of 6 minutes as previously described42. Each mouse was considered 
immobile when it hung passively and completely motionless. The total immobility period was recorded and com-
pared to vehicle control group.
Locomotive activity. Locomotor activity (ambulations) was measured by using a computerised Actophotometer 
(IMCORP, India). An array of 16 infrared emitter/detector pairs measured animal activity along a single axis 
of motion, the digital data being displayed on the front panel as ambulatory movements. Mice were allowed to 
acclimatise to the observation chamber for a period of 2 minutes. The activity was monitored continuously for a 
period of 15 minutes. Locomotion was expressed in terms of total photobeam counts per 15 minutes per animal 
and compared to vehicle control groups as previously described41.
In vivo cancer mouse model. Animals. Naval Medical Research Institute (NMRI) mice weighing 25 g 
were used for tumour transplantation, they were kept on a 12 hour day-night cycle, at ambient temperature, with 
free access to food (standard chow diet, Special Diet Services, Lillico, Wonham Mill, Bletchworth Surrey, UK) and 
water, the consumption of which was monitored throughout the experiments.
MAC13 cancer model transplant and treatment. The NMRI mice were transplanted with a fragment of mouse 
adenocarcinoma (MAC13) in the flank, by means of a trocar43. Twelve days after the tumour was implanted, 
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animals (6 animals per group) were treated, with either ammonium salt (10 mg.kg−1 i.v., via the tail vein) or 
control (100 μl PBS i.v., via the tail vein) daily. Animals were terminated before the tumour exceeded 1 cm³. The 
tumour diameters were measured daily from day 12 using a micrometer. Animal studies were conducted under 
Home Office License according to the U.K. Coordinating Committee on Cancer Research Guidelines for the 
Care and Use of Laboratory Animals. The experimental protocols were approved by Aston University Ethics 
Committee.
Data analysis. Saturation and competition data were analysed using non-linear regression analysis 
(GraphPad Prism, version 6.0 h for Macintosh) to fit saturation curves and calculate maximal radioligand binding 
and dissociation constants. In order to give a more true representation of the drugs’ affinities for the receptor, the 
IC50 was converted to a Ki (where the Hill slope was near unity) value using the Cheng Prusoff equation. Values 
were converted into pKd or pKi before any mathematical manipulation to ensure normal distribution. Data are 
presented as mean ± SEM.
Comparisons of Hill slope were performed using a one-sample t test (GraphPad Prism, version 6.0 h for 
Macintosh), comparing values to unity. P < 0.05 was considered statistically significant.
MTS and protein assays were read using a Versamax plate reader, and the data collected using Softmax Pro 
software.
Results from behavioural assays and tumour studies are expressed as mean ± SEM. Significance of differences 
was determined using one-way ANOVA followed by a Dunnett’s (when comparing against a control group) or 
Tukey’s (when comparing all means) post hoc test. P < 0.05 was considered statistically significant.
Protein measurements. Protein amounts were determined using Bio-Rad Protein Dye Reagent, based on 
Coomassie Brilliant Blue G250 (Bio-Rad, Hemel Hempstead, UK). BSA was used to prepare standards.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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